Both products, known as LixiLan and IDegLira during clinical trials, were delayed by 3 months at the U.S. Food and Drug Administration (FDA) following recommendations for approval from FDA panels back in May. And yet the FDA has approved the two new competing combination products containing fixed doses of glucagonlike-peptide 1 (GLP-1) receptor agonists and long-acting insulins, from Sanofi and Novo Nordisk respectively, for the treatment of adults with type 2 diabetes.